Financial Performance - The company's operating revenue for 2024 reached ¥194,915,924.94, representing a year-on-year increase of 2.51%[24]. - Net profit attributable to shareholders for 2024 was ¥44,290,403.28, reflecting a growth of 14.23% compared to the previous year[27]. - The net cash flow from operating activities increased by 53.12% year-on-year, amounting to ¥50,253,408.63[27]. - The basic earnings per share for 2024 was ¥0.41, up 13.89% from the previous year[25]. - The company's total assets at the end of 2024 were ¥1,120,033,956.92, showing a slight decrease of 0.75% from the previous year[24]. - The company's net assets attributable to shareholders increased by 0.89% year-on-year, totaling ¥1,095,500,608.75 at the end of 2024[24]. - The comprehensive gross profit margin increased by 2.35 percentage points, and net cash flow from operating activities grew by 53.12% year-on-year[39]. - The total cash dividend for 2024, including the interim distribution, amounts to 34,630,400.00 RMB, representing 78.19% of the net profit attributable to shareholders in the consolidated financial statements for 2024[8]. Research and Development - The company made significant progress in R&D, with key projects like the anti-cobra venom serum entering clinical trial phases[40]. - The total R&D investment for the year is approximately ¥23.84 million, a decrease of 21.61% compared to the previous year[86]. - The company has received authorization for 7 invention patents during the reporting period, bringing the total to 20[84]. - The company has developed core proprietary technologies for the preparation of safe, effective, and stable emergency treatment drugs[75]. - The company is conducting clinical trials for five major projects, including the development of antivenom for viper bites, with a total expected investment of 2,570.00 million RMB and current period investment of 190.01 million RMB[87]. - The company is committed to developing rapid diagnostic reagents for snake venom, aiming to meet clinical needs and create new growth points[161]. - The company is actively pursuing market expansion and innovation in its product offerings, focusing on the development of new biopharmaceuticals and medical devices[140]. Market Position and Products - The company is the sole producer and seller of snake antivenom in China, providing critical emergency treatment for snake bites[46]. - The company holds several patents, including methods for preparing specific polyclonal antibodies against snake venom, enhancing its competitive edge in the market[40]. - The company aims to increase the coverage of its anti-snake venom serum products, which currently only reach a few thousand patients each year due to competition from traditional Chinese medicine[65]. - The company’s main products include anti-viper venom serum, equine tetanus immunoglobulin, and rabies serum, all of which are positioned as leading products in their respective categories[63]. - The company is preparing for the market launch of the anti-rabies serum, which is expected to be a new growth point for performance[42]. - The company is focused on expanding its market presence and improving clinical treatment standards for snakebite injuries, which is expected to drive demand for its products[42]. Governance and Compliance - The company emphasizes effective communication with investors through various channels, including performance briefings and investor hotlines[170]. - The company is committed to optimizing its governance structure and internal controls to protect shareholder rights and promote sustainable development[166]. - The company held two shareholder meetings during the reporting period, ensuring compliance with legal and regulatory requirements[173]. - The board of directors convened eight times, successfully completing board elections and adhering to governance regulations[167]. - The supervisory board met seven times, maintaining compliance with legal frameworks and ensuring oversight of company operations[168]. - The company has not faced any penalties from securities regulatory agencies in the past three years[186]. Risks and Challenges - The company has detailed various operational risks in the report, which investors are advised to review[5]. - Future risks include potential price controls or competition leading to price reductions, which could impact revenue growth and profitability[99]. - The company faces risks related to product safety, particularly concerning the potential presence of pathogens in its antivenom products despite stringent screening measures[98]. - The company has a risk of supply shortages for horses used in the production of antivenom serum due to limited suppliers and potential quarantine issues[101]. - The company faces risks from increased market competition for its main products, which could lead to price declines or reduced market share[103]. Employee and Management - The total number of employees in the parent company and major subsidiaries is 326, with 255 in the parent company and 71 in subsidiaries[198]. - The company has implemented a competitive and incentive-based compensation policy, ensuring timely payment of social insurance and housing fund for all employees[199]. - Employee benefits include free lunch, dormitory, free shuttle bus, high-temperature allowance, annual health check-ups, holiday benefits, birthday benefits, and special benefits for female employees[199]. - The company emphasizes employee training, with annual training plans focusing on practical skills, professional knowledge, and career development[200]. - The company appointed Liu Jinbao as the new CFO effective February 2025, following the resignation of Li Shaoyang for personal reasons[180]. Strategic Plans - The company plans to expand its product line in the anti-serum and anti-toxin sector, focusing on new indications for biological toxin-related diseases, with several products in preclinical or clinical research stages[159]. - The company plans to enhance its product pipeline to improve treatment efficiency for snakebite injuries, thereby expanding its competitive advantage in this field[162]. - The company aims to enhance academic promotion of its products and strengthen market insights, focusing on expanding the market for snake antivenom and rabies serum[162]. - The company plans to accelerate the R&D of new products, including rapid diagnostic kits for snake venom, with clinical studies for cobra venom tests expected to be completed in 2025[162].

Financial Performance - The company's operating revenue for Q1 2025 was ¥25,621,279.55, a decrease of 2.59% compared to ¥26,301,356.47 in the same period last year[4] - Net profit attributable to shareholders increased by 154.77% to ¥3,757,316.22 from ¥1,474,787.04 year-on-year[4] - Basic and diluted earnings per share rose by 200.00% to ¥0.03 from ¥0.01 in the previous year[4] - Total operating revenue for Q1 2025 was ¥25,621,279.55, a decrease of 2.58% from ¥26,301,356.47 in Q1 2024[18] - Net profit for Q1 2025 was ¥3,757,316.22, significantly up from ¥1,474,787.04 in Q1 2024, marking an increase of 154.5%[19] - Basic and diluted earnings per share for Q1 2025 were both ¥0.03, compared to ¥0.01 in Q1 2024[19] - Total comprehensive income for Q1 2025 was ¥3,757,316.22, compared to ¥1,474,787.04 in Q1 2024, reflecting a strong performance[19] Research and Development - Total R&D investment was ¥3,182,878.72, down 48.68% from ¥6,202,207.19 in the same period last year, with R&D expenses accounting for 12.42% of operating revenue, a decrease of 11.16 percentage points[5] - Research and development expenses decreased to ¥3,182,878.72 in Q1 2025 from ¥6,202,207.19 in Q1 2024, a reduction of 48.7%[18] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥20,933,375.96, slightly improved from -¥21,796,451.38 in the previous year[4] - Cash flow from operating activities for Q1 2025 was negative at -¥20,933,375.96, slightly improved from -¥21,796,451.38 in Q1 2024[22] - Cash flow from investing activities generated a net inflow of ¥189,750,738.98 in Q1 2025, compared to a net outflow of -¥5,046,128.03 in Q1 2024[23] - The ending cash and cash equivalents balance for Q1 2025 was ¥350,924,252.18, up from ¥124,093,875.96 in Q1 2024[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,116,016,974.45, a decrease of 0.36% from ¥1,120,033,956.92 at the end of the previous year[5] - The company's total liabilities decreased to ¥17,122,128.87 from ¥24,533,348.17, a reduction of 30.3%[15] - The total assets as of March 31, 2025, were ¥1,116,016,974.45, down from ¥1,120,033,956.92, a decrease of 0.4%[14] - The company's equity attributable to shareholders increased to ¥1,098,894,845.58 from ¥1,095,500,608.75, a rise of 0.2%[15] - The total current assets decreased slightly to ¥912,262,557.85 from ¥916,362,945.70, a decline of 0.4%[13] - Accounts receivable increased to ¥49,203,485.97 from ¥36,678,957.69, reflecting a growth of 34.0%[13] - The inventory level rose to ¥47,473,661.57 from ¥43,275,462.94, an increase of 9.1%[13] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 7,061[8] - Major shareholders include Zhao Aixian with 34.05% and Shanghai Zhiyuan Investment Co., Ltd. with 22.18% of shares[9] - The company has not reported any significant changes in its major shareholders or their shareholdings during the reporting period[10] Other Information - The company reported non-recurring gains of ¥3,825,059.39, primarily from bank wealth management income and government subsidies[7] - There are no new strategies or major product developments mentioned in the current report[11] - The company reported a significant increase in investment income, rising to ¥2,266,175.69 in Q1 2025 from ¥645,457.55 in Q1 2024[18] - The company reported a significant decrease in short-term borrowings, reflecting improved liquidity management[15]

上海赛伦生物技术股份有限公司 内 部 控 制 审 计 报 告 天职业字[2025]7682 号 录 目 内 部 控 制 审 计 报 告 - l 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行查询 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行查询 "我在 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计了上 海赛伦生物技术股份有限公司(以下简称"赛伦生物")2024年 12月 31 日的财务报告内部 控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指引》 的规定,建立健全和有效实施内部控制,并评价其有效性是赛伦生物董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表审计意见, 并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外,由于情况的变化 可能导致内部控制 ...

关于上海赛伦生物技术股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 2、 附表 委托单位：上海赛伦生物技术股份有限公司 审计单位：天职国际会计师事务所（特殊普通合伙） 联系电话：021-64959122 上海赛伦生物技术股份有限公司 控 股 股 东 及 其 他 关 联 方 资 金 占 用 情 况 的 专 项 说明 天职业字[2025]7686 号 控股股东及其他关联方资金占用情况的专项说明 天职业字[2025] 7686 号 上海赛伦生物技术股份有限公司董事会: 我们审计了上海赛伦生物技术股份有限公司(以下简称"赛伦生物")财务报表,包括2024 年12月31日的合并及母公司资产负债表、2024年度的合并及母公司利润表、合并及母公司现 金流量表、合并及母公司股东权益变动表以及财务报表附注,并于2025年4月25日签署了无保 留意见的审计报告。 根据中国证监会、公安部、国资委、中国银保监会《上市公司监管指引第8号 -- 上市公 司资金往来、对外担保的监管要求》和证券交易所相关文件要求,赛伦生物编制了后附的2024 年度非经营性资金占用及其他关联资金往来情况 ...

上 海 赛 伦 生 物 技 术 股 份 有 限 公 司 募 集 资 金 存 放 与 实 际 使 用 情 况 鉴 证 报 告 天 职 业 字 [2025]7684 号 录 目 募集资金存放与实际使用情况鉴证报告- l 关于公司募集资金存放与实际使用情况的专项报告- 3 您可使用手机"扫一扣"或遗入"注册会计师行业统一般管平台（http://ace.mof.gov.cn）"进行查询 您可使用手机"扫一扫"或遗入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行查询 "我 募集资金存放与实际使用情况鉴证报告 天职业字[2025]7684 号 上海赛伦生物技术股份有限公司全体股东: 我们审核了后附的上海赛伦生物技术股份有限公司(以下简称"赛伦生物")《关于公司 募集资金存放与实际使用情况的专项报告》。 一、管理层的责任 赛伦生物管理层的责任是按照中国证监会《上市公司监管指引第2号 -- 上市公司募集资 金管理和使用的监管要求》、上海证券交易所颁布的《上海证券交易所科创板上市公司自律监 管指引第 1 号 -- 规范运作》及相关格式指引规定编制《关于公司募集资金存放与实际使用情 况的专项报告 ...

方正证券承销保荐有限责任公司 关于上海赛伦生物技术股份有限公司 2024 年度募集资金存放与实际使用情况的专项核查意见 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意上海赛伦生物技术股份有限公司首 次公开发行股票注册的批复》（证监许可[2022]204 号）的批准，公司获准向社 会公开发行人民币普通股 2,706 万股，每股面值为 1.00 元，每股发行价格为 33.03 元，公司收到募集资金总额为 89,379.18 万元，扣除发行费用 10,886.82 万元，募 集资金净额为 78,492.36 万元。上述募集资金已于 2022 年 3 月 4 日全部到位，并 存放于募集资金专项账户内。天职国际会计师事务所（特殊普通合伙）于 2022 年 3 月 4 日出具了《验资报告》（天职业字[2022]9819 号）。 截至 2024 年 12 月 31 日，公司累计使用募集资金 235,991,635.58 元，募集 资金余额为 603,771,067.03 元。2024 年度，公司募集资金使用及余额情况如下： | 项目 | 金额（元） | | --- | --- | | 截至2023年12月31日 ...

Group 1 - The company will hold an investor briefing on April 30, 2025, from 09:00 to 10:00 [2][4] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [2][4] - The company plans to release its 2024 annual report and 2025 Q1 report on April 26, 2025, to provide investors with insights into its financial performance [2][3] Group 2 - Investors can participate in the briefing by logging into the Shanghai Stock Exchange Roadshow Center website on the scheduled date [5] - A pre-collection of questions will be available from April 23 to April 29, 2025, allowing investors to submit inquiries via the website or email [5] - The company will address commonly asked questions during the briefing to enhance investor understanding [3][5] Group 3 - Key personnel attending the briefing include the Chairman, General Manager, and other board members, with potential adjustments based on special circumstances [4] - The company’s Board Secretary Office is the contact department for any inquiries related to the briefing [6][7] - After the briefing, investors can access the main content and details of the event on the Shanghai Stock Exchange Roadshow Center [7]

证券代码：688163 证券简称：赛伦生物 公告编号：2025-005 上海赛伦生物技术股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025 年 4 月 30 日 （星期三） 09:00-10:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 4 月 23 日（星期三）至 4 月 29 日（星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 dmb@serum-china.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 1 （二） 会议召开地点：上证路演中心（网址：http://roadshow.sseinfo.com/） （三） 会议召开方式：上证路演中心网络互动 三、参加人员 公司董 ...

天职国际作为公司聘任的 2024 年度财务报表及内部控制审计机构，原指派 王巍先生作为项目质量控制复核人。鉴于原项目质量控制复核人王巍因内部工作 调整，现委派张磊接替王巍作为公司项目质量控制复核人，继续完成公司 2024 年年度财务报表和内部控制审计等质量控制复核工作。变更后的项目质量控制复 核人为张磊。 二、本次变更人员的基本信息、诚信记录和独立性情况 证券代码：688163 证券简称：赛伦生物 公告编号：2025-004 上海赛伦生物技术股份有限公司 关于审计机构变更项目质量控制复核人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海赛伦生物技术股份有限公司（以下简称 "公司"）于 2024 年 4 月 26 日 分别召开了第三届董事会第二十次会议及第三届监事会第十五次会议，于 2024 年 5 月 20 日召开了 2023 年年度股东大会，审议通过了《关于续聘公司 2024 年 度审计机构的议案》，同意续聘天职国际会计师事务所（特殊普通合伙）（以下简 称"天职国际"）为公司 2024 年度审计机构，具体内容 ...